CD20

[Cancer Immunology Research] Investigators tested the in vitro effect of different NK cell engagers, which triggered either NKp46 or NKp30 together with CD16A, and target either CD19 or CD20 to induce killing of pediatric B cell precursor acute lymphoblastic leukemia.

[Annals of Neurology] Scientists investigated prospectively humoral and cellular responses to SARS-CoV-2 mRNA vaccination in 82 patients with neuroimmunologic disorders on anti-CD20 therapy and 82 age- and sex-matched healthy controls.

[Mustang Bio, Inc.] Mustang Bio, Inc. announced updated data from the ongoing Phase I/II clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.

[TG Therapeutics, Inc.] TG Therapeutics, Inc. announced the submission of a Biologics License Application to the FDA requesting approval of ublituximab, the company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis.

[Nature Medicine] The authors investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis on anti-CD20 antibody monotherapy compared with healthy controls after BNT162b2 or mRNA-1273 mRNA vaccination.

[BeiGene, Ltd.] BeiGene, Ltd. announced that BRUKINSA® (zanubrutinib) has received accelerated approval from the US FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen.